Drug-Induced Liver Disorders

Drug-induced hepatotoxicity is a frequent cause of liver disease. Although often presenting as acute hepatitis and/or cholestasis, virtually any clinicalpathological pattern of acute or chronic liver disease can occur. Most reactions occur in a small proportion of the population using a particular drug. Each drug associated with hepatotoxicity tends to have a characteristic signature regarding latency and pattern of injury. The mechanism can be drug metabolism-dependent or related to the chemical properties of the parent drug. The former are immune mediated or due to metabolic idiosyncrasy. Monitoring serum ALT levels is of unproven effectiveness but should be considered when there is an increased risk of delayed onset serious hepatitis-like reactions. The key for the future is improved identification of toxic potential in preclinical studies, clinical trials and postmarketing experience. The elucidation of the genetic and environmental mechanisms contributing to delayed idiosyncratic reactions is a major barrier to overcome in this field.

[1]  P. Watkins,et al.  Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.

[2]  S. Spielberg,et al.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. , 1988, The Journal of clinical investigation.

[3]  M. Rieder,et al.  Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions , 1991, Clinical pharmacology and therapeutics.

[4]  V. Desmet,et al.  Nimesulide-induced acute hepatitis: evidence from six cases. , 1998, Journal of hepatology.

[5]  N. Mcintyre,et al.  Anti-tuberculosis medication and the liver: dangers and recommendations in management. , 1995, The European respiratory journal.

[6]  V. Desmet.  Vanishing bile duct syndrome in drug-induced liver disease. , 1997, Journal of hepatology.

[7]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.

[8]  D. Larrey,et al.  Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. , 1992, Gut.

[9]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[10]  D. Pessayre,et al.  Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. , 1998, Gastroenterology.

[11]  K. Ishak,et al.  Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. , 1993, Gastroenterology.

[12]  C. Bénichou.  Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[13]  R. Andrade,et al.  Comparison of two clinical scales for causality assessment in hepatotoxicity , 2001, Hepatology.

[14]  G. Mazariegos,et al.  Acute liver failure: Clinical features, outcome analysis, and applicability of prognostic criteria , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  M. Rieder,et al.  Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. , 1989, Annals of internal medicine.

[16]  J H Lewis,et al.  Drug-induced liver disease. , 2000, Clinics in liver disease.

[17]  D. Pessayre,et al.  Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. , 1997, Journal of hepatology.

[18]  C. Degott,et al.  Drug‐induced prolonged cholestasis in adults: A histological semiquantitative study demonstrating progressive ductopenia , 1992, Hepatology.

[19]  J. Neuberger.  IMMUNE MECHANISMS IN DRUG HEPATOTOXICITY , 1998 .

[20]  H. Zimmerman,et al.  Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure , 1995, Hepatology.

[21]  R. Victorino,et al.  Development and validation of a clinical scale for the diagnosis of drug‐induced hepatitis , 1997, Hepatology.

[22]  P. Moses,et al.  Severe hepatotoxicity associated with bromfenac sodium , 1999, American Journal of Gastroenterology.

[23]  J. Belaiche,et al.  Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid , 1995, Hepatology.

[24]  A. Flahault,et al.  Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. , 1993, Journal of clinical epidemiology.

[25]  N. Kaplowitz.  Causality assessment versus guilt‐by‐association in drug hepatotoxicity , 2001, Hepatology.

[26]  P. Beaune,et al.  Immunotoxicology of the liver: adverse reactions to drugs. , 1997, Journal of hepatology.

[27]  A. Makin,et al.  Paracetamol hepatotoxicity and alcohol consumption in deliberate and accidental overdose. , 2000, QJM : monthly journal of the Association of Physicians.

[28]  J. Tredger,et al.  Drug metabolism and hepatotoxicity. , 1991, Gut.

[29]  T. Davern,et al.  Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. , 2000, Digestive diseases and sciences.

[30]  E. Keeffe,et al.  Hepatotoxicity of transplant immunosuppressive agents. , 1995, Gastroenterology clinics of North America.

[31]  S. Spielberg,et al.  Familial occurrence of hypersensitivity to phenytoin. , 1991, The American journal of medicine.